Jennifer Chow discusses promising results of cltx C therapy, signaling future trials and regulatory milestones in cancer treatment | Jennifer Chow, CEO,Chimeric Therapeutics Ltd. 00:10:00
Advancements in cancer treatment, particularly with cltx C therapy, were discussed by Jennifer Chow leading biotech company, showcasing a 55% Disease Control rate and promising safety profiles, with plans for phase 1B trials and further regulatory approvals outlined.